Home > Engagements


Alleged anticompetitive agreement in the market for plasma derivates

The Italian Competition Authority in 2018 held an investigation into Kedrion and Grifols, two providers of plasma derivatives, for their joint participation to a tender launched by the Italian Healthcare System. The Italian Competition Authority was concerned that the joint bid had unduly restricted competition for the award of the tender. Lear’s analyses successfully showed that the agreement had no anticompetitive effects and that it provided significant benefits to the Italian Healthcare System.